Biller Jonathan 4

What Happened
Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), reported dispositions on 2026-02-13 totaling 3,981 shares for roughly $1.95 million. The filing shows 2,993 shares were disposed at $487.76 each (total $1,459,866) to satisfy exercise price or tax liability, and a separate open‑market sale of 988 shares at $499.00 each (total $493,012). These transactions are sales (not purchases).

Key Details

• Transaction date: 2026-02-13. Prices: $487.76 (2,993 shares, F — payment for exercise/tax) and $499.00 (988 shares, S — open market).
• Gross proceeds: $1,459,866 (F) + $493,012 (S) = $1,952,878 (~$1.95M).
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: Transactions were made pursuant to Mr. Biller’s company‑approved Rule 10b5‑1 trading plan entered 02/24/2025.
• Filing date: 2026-02-18 — filed within the required two business-day window (note: Feb 16 was a federal holiday).

Context
The 2,993-share disposition (code F) indicates shares were surrendered/withheld to cover exercise costs or tax obligations related to a derivative exercise; the additional 988 shares were sold in the open market. The trades were executed under a pre-established 10b5‑1 plan, which typically means the transactions were planned in advance and follow a preset schedule rather than being timed to current company developments. As with most insider sales, this is routine reporting of liquidity rather than a direct signal of company outlook.